Life Sciences

Inceptua Group and Cycle Pharmaceuticals Partner for a Free Goods Programme for Patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU)

Life Science Newswire Inceptua Group (Inceptua) and Cycle Pharmaceuticals Ltd (Cycle) have announced a partnership to make NITYR® (nitisinone) Tablets available via a Free Goods Programme for eligible patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU).

HT-1 and AKU are both ultra-rare diseases. HT-1 affects about 1 in 100,000 individuals worldwide,¹ whilst AKU affects 1 in 250,000 to 1 million people worldwide.²

A Free Goods Programme is a compliant way for medicines that are not approved in their country of intended use to be made available for patients who either have no alternative treatment option or have exhausted all other treatment options available in their country of residence.

Cycle has an existing Free Goods Programme with patients with HT-1 in India, Bangladesh, Paki-stan, and Sudan. Inceptua will support Cycle through the expansion of the Free Goods Programme to include further countries where NITYR is not commercially available, or where the local healthcare system is unable to afford this medication. Countries in scope of the NITYR Free Goods Programme include Argentina, Bangladesh, Brazil, Chile, Colombia, Dominican Republic, Jordan, Mexico, Nigeria, Pakistan, Peru, Tunisia, and Turkey.

Cycle is committed to supporting patients on the Free Goods Programme for the duration of their lifetime.

Stuart Bell, Senior Vice President, Inceptua Early Access said, “Inceptua is proud to partner with Cycle in this Free Goods Programme to allow access to NITYR to a broader number of countries and patients. Cycle’s ethos around medicine provision aligns very closely to those of Inceptua’s, and we look forward to supporting patients with no other treatment options for these devastating diseases”.

James Harrison, CEO of Cycle Pharmaceuticals said, “Right from the beginning of Cycle’s story in 2012, we made a commitment to provide a Free Goods Programme for rare disease patients that can-not otherwise access our medicines.  The whole Cycle team is extremely proud and humbled to be able to expand the NITYR Free Goods Programme. It really matters”.